SLC6A3 and Parkinsonism: Indeed, studies performed in two nonhuman primate species, the common marmoset and the cynomolgus macaque, have shown similar results that is monotherapy with selective DAT inhibitors reverse parkinsonism to an extent comparable to L-DOPA.